Itraconazole - How It Works
Clinical pharmacology details from the US FDA-approved label: how Itraconazole works in your body, how it's absorbed, how long it stays active, and how it's eliminated.
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
As a consequence of non-linear pharmacokinetics, itraconazole accumulates in plasma during multiple dosing.
Steady-state concentrations are generally reached within about 15 days, with C max values of 0.5 mcg /mL, 1.1 mcg /mL and 2.0 mcg/mL after oral administration of 100 mg once daily, 200 mg once daily and 200 mg b.i.d., respectively.
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment.
Itraconazole mean total plasma clearance following intravenous administration is 278 mL/min.
Itraconazole clearance decreases at higher doses due to saturable hepatic metabolism.
Absorption Itraconazole is rapidly absorbed after oral administration.
Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following an oral capsule dose.
The observed absolute oral bioavailability of itraconazole is about 55%.
The oral bioavailability of itraconazole is maximal when itraconazole capsules are taken immediately after a full meal.
Absorption of itraconazole capsules is reduced in subjects with reduced gastric acidity, such as subjects taking medications known as gastric acid secretion suppressors (e.g., H 2 -receptor antagonists, proton pump inhibitors) or subjects with achlorhydria caused by certain diseases. (See PRECAUTIONS: Drug Interactions.) Absorption of itraconazole under fasted conditions in these subjects is increased when itraconazole capsules are administered with an acidic beverage (such as a non-diet cola).
When itraconazole capsules were administered as a single 200-mg dose under fasted conditions with non-diet cola after ranitidine pretreatment, a H 2 -receptor antagonist, itraconazole absorption was comparable to that observed when itraconazole capsules were administered alone. (See PRECAUTIONS: Drug Interactions.) Itraconazole exposure is lower with the Capsule formulation than with the Oral Solution when the same dose of drug is given. (See WARNINGS.) Distribution Most of the itraconazole in plasma is bound to protein (99.8%), with albumin being the main binding component (99.6% for the hydroxy-metabolite).
It has also a marked affinity for lipids.
Only 0.2% of the itraconazole in plasma is present as free drug.
Itraconazole is distributed in a large apparent volume in the body (>700 L), suggesting extensive distribution into tissues.
Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma, and the uptake into keratinous tissues, skin in particular, up to four times higher.
Concentrations in the cerebrospinal fluid are much lower than in plasma.
Metabolism Itraconazole is extensively metabolized by the liver into a large number of metabolites.
In vitro studies have shown that CYP3A4 is the major enzyme involved in the metabolism of itraconazole.